Privia Health Group (NASDAQ:PRVA – Free Report) had its price target trimmed by JPMorgan Chase & Co. from $43.00 to $38.00 in a report issued on Friday morning, Benzinga reports. They currently have an overweight rating on the stock.
A number of other brokerages have also commented on PRVA. UBS Group cut their target price on Privia Health Group from $35.00 to $32.00 and set a buy rating for the company in a research note on Friday, August 18th. TD Cowen lowered their price objective on Privia Health Group from $44.00 to $35.00 and set an outperform rating on the stock in a research note on Tuesday, August 15th. Finally, Evercore ISI cut their target price on Privia Health Group from $32.00 to $26.00 in a research report on Wednesday, October 11th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Privia Health Group presently has a consensus rating of Buy and an average price target of $34.64.
Privia Health Group Price Performance
Privia Health Group (NASDAQ:PRVA – Get Free Report) last released its earnings results on Friday, November 3rd. The company reported $0.05 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.05. The business had revenue of $417.30 million for the quarter, compared to the consensus estimate of $410.51 million. Privia Health Group had a return on equity of 6.80% and a net margin of 2.40%. The firm’s revenue for the quarter was up 21.7% compared to the same quarter last year. During the same period last year, the business earned $0.01 earnings per share. Analysts expect that Privia Health Group will post 0.21 earnings per share for the current fiscal year.
Insider Activity at Privia Health Group
In other Privia Health Group news, Director William M. Sullivan sold 18,153 shares of the business’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $26.46, for a total value of $480,328.38. Following the transaction, the director now owns 5,528,637 shares of the company’s stock, valued at $146,287,735.02. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, EVP Thomas Bartrum sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $25.77, for a total value of $386,550.00. Following the completion of the sale, the executive vice president now owns 106,114 shares of the company’s stock, valued at $2,734,557.78. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director William M. Sullivan sold 18,153 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $26.46, for a total transaction of $480,328.38. Following the completion of the transaction, the director now owns 5,528,637 shares of the company’s stock, valued at approximately $146,287,735.02. The disclosure for this sale can be found here. Insiders sold 51,306 shares of company stock valued at $1,321,248 in the last three months. Corporate insiders own 57.60% of the company’s stock.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of PRVA. C M Bidwell & Associates Ltd. acquired a new position in shares of Privia Health Group during the 2nd quarter worth about $38,000. Tower Research Capital LLC TRC boosted its position in shares of Privia Health Group by 171.1% during the first quarter. Tower Research Capital LLC TRC now owns 1,578 shares of the company’s stock worth $44,000 after purchasing an additional 996 shares in the last quarter. Point72 Hong Kong Ltd acquired a new position in shares of Privia Health Group in the 1st quarter valued at $47,000. Park Place Capital Corp increased its position in shares of Privia Health Group by 81.3% in the 2nd quarter. Park Place Capital Corp now owns 1,867 shares of the company’s stock valued at $49,000 after buying an additional 837 shares in the last quarter. Finally, Neo Ivy Capital Management bought a new stake in shares of Privia Health Group in the 2nd quarter valued at $53,000. Institutional investors own 92.40% of the company’s stock.
About Privia Health Group
Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.
- Five stocks we like better than Privia Health Group
- Want to Profit on the Downtrend? Downtrends, Explained.
- The most upgraded stocks in November have two things in common
- What is the Shanghai Stock Exchange Composite Index?
- Monday.com rocked earnings like it’s the weekend
- How Can Investors Benefit From After-Hours Trading
- Plan to own one retailer? Make it this one
Receive News & Ratings for Privia Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Privia Health Group and related companies with MarketBeat.com's FREE daily email newsletter.